Seasoned healthcare operator and strategic investor with experience building growth-stage services and technology businesses for payors and providers. J. Derieck Hodges has led corporate development, M&A and commercial strategy roles, and sits on industry boards advising scaling and go-to-market execution. Market-facing skills include commercial partnerships, capital formation and operational turnarounds; engages with private equity and venture investors on health sector deals.
Seasoned healthcare operator and strategic investor with experience building growth-stage services and technology businesses for payors and providers. J. Derieck Hodges has led corporate development, M&A and commercial strategy roles, and sits on industry boards advising scaling and go-to-market execution. Market-facing skills include commercial partnerships, capital formation and operational turnarounds; engages with private equity and venture investors on health sector deals.
Operates as a growth‑oriented healthcare investor focusing on services and healthtech businesses serving payors and providers. Prefers equity and structured minority stakes to accelerate commercial scale, partnering with management on go‑to‑market, partnerships and operational turnarounds. Investment decisions hinge on measurable clinical or cost outcomes, predictable revenue models, and defensible distribution channels. Time horizon is growth-cycle oriented (3–7 years), with active portfolio governance, disciplined capital allocation, and readiness to syndicate alongside PE and venture partners to de‑risk execution.
Operates as a growth‑oriented healthcare investor focusing on services and healthtech businesses serving payors and providers. Prefers equity and structured minority stakes to accelerate commercial scale, partnering with management on go‑to‑market, partnerships and operational turnarounds. Investment decisions hinge on measurable clinical or cost outcomes, predictable revenue models, and defensible distribution channels. Time horizon is growth-cycle oriented (3–7 years), with active portfolio governance, disciplined capital allocation, and readiness to syndicate alongside PE and venture partners to de‑risk execution.
| Trades 88 | Longs Won 71/88 80% | Profit Factor 23.9 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $339,637.39 |
| Average Win $237,987.4 | Best Trade (Jun 15) $1.98M | Sharpe Ratio -868.88 |
| Average Loss -$41,590.48 | Worst Trade (Jun 14) -$360,980.89 | Z-Score 14.92 (100%) |
| Commissions $0 | Avg. Trade Length 1y 5m 2w 2d | Expectancy $183,978.03 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 2,237 | 2,013 | 1,790 | 1,566 | 1,342 | 1,119 | 895 | 671 | 447 | 224 |